
Shahla discusses a recent real-world study analyzing the clinical outcomes of patients prescribed paltusotine after its September 2025 approval.

Leena Shahla, MD, is the medical director at the Duke Pituitary Center and an associate professor of medicine and neurosurgery at Duke University.

Shahla discusses a recent real-world study analyzing the clinical outcomes of patients prescribed paltusotine after its September 2025 approval.